PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14 by M. Hultcrantz, D. Kleinman, P. Ghataorhe, A. Mckeown, W. He, T. Ling, R. C. Jewell, J. Byrne, L. Eliason, E. Scott, J. Opalinska

Get full text

S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA by T. Akhlaghi, K. Maclachlan, N. Korde, S. Mailankody, A. Lesokhin, H. Hassoun, S. X. Lu, D. Patel, U. Shah, C. Tan, A. Derkach, O. Lahoud, H. J. Landau, G. L. Shah, M. Scordo, D. J. Chung, S. A. Giralt, S. Z. Usmani, O. Landgren, M. Hultcrantz

Get full text

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS by T. Akhlaghi, K. Maclachlan, N. Korde, S. Mailankody, A. Lesokhin, H. Hassoun, S. X. Lu, D. Patel, U. Shah, C. Tan, A. Derkach, O. Lahoud, H. J. Landau, G. L. Shah, M. Scordo, D. J. Chung, S. A. Giralt, S. Z. Usmani, O. Landgren, M. Hultcrantz

Get full text

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL by A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial

Get full text

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... by S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia

Get full text